Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Zevra Therapeutics (ZVRA) over the last 9 years, with Q3 2025 value amounting to $685000.0.

  • Zevra Therapeutics' Amortization of Deferred Charges fell 1206.68% to $685000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 7709.87%. This contributed to the annual value of $2.1 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Zevra Therapeutics reported Amortization of Deferred Charges of $685000.0 as of Q3 2025, which was down 1206.68% from $689000.0 recorded in Q2 2025.
  • Zevra Therapeutics' Amortization of Deferred Charges' 5-year high stood at $779000.0 during Q3 2024, with a 5-year trough of $150000.0 in Q1 2021.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $631500.0 (2024), whereas its average is $534500.0.
  • In the last 5 years, Zevra Therapeutics' Amortization of Deferred Charges tumbled by 8794.21% in 2021 and then soared by 17740.59% in 2025.
  • Quarter analysis of 3 years shows Zevra Therapeutics' Amortization of Deferred Charges stood at $150000.0 in 2021, then soared by 300.0% to $600000.0 in 2024, then rose by 14.17% to $685000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $685000.0 for Q3 2025, versus $689000.0 for Q2 2025 and $663000.0 for Q1 2025.